[Malignant gliomas].
Glial tumors represent 2000 to 3000 new cases per year in France and 75% of them are of high grade. Recent understanding of the molecular biology of these tumors revealed the importance of 1p19q codeletion and mgMT promotor methylation. Radiotherapy also recently evolved with the progress in medical imaging which allows a better definition of the target volumes. Even modest, therapeutic progress is based on chemoradiotherapy with temozolomide and on the development of non-coplanar conformational radiotherapy. Knowledge and precise evaluation of potential late effects of our treatments is necessary due to actual improvement of survival with chemoradiotherapy in glioblastoma.
Service d'oncologie radiothérapique, centre des tumeurs, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
S
S
Haberer
A
A
Assouline
J-J
JJ
Mazeron
D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy*; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D019175:DNA Methylation; D005910:Glioma / Q000000981:diagnostic imaging / Q000235:genetics / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D011401:Promoter Regions, Genetic; D011859:Radiography; D017384:Sequence Deletion; D015996:Survival Rate